Short answer. HHS may revisit this interim policy, in whole or in part, if a safety signal or a product-quality issue arises with a compounded product inside its scope [1][2]. The notice also says the draft establishes no rights and is not binding [1]. As of Oct 29, 2026.

Interim means it has an end in view

The policy applies until a peptide is addressed in a final rule as included on the 503A bulks list or not included [2]. A final rule could add some, add all, or add none. The notice says future rulemakings may propose adding some or all, based on the evidence [1].

Between now and that rule, HHS has already reserved the right to pull back [1]. A safety report, a contamination problem, or another product-quality issue is the kind of thing the notice names. That is why the reporting condition exists [2].

What not to build on it

Do not sign a long prepaid plan for one of these six on the theory that October 28 locked the law in place. The notice says the opposite about rights [1]. Do not stock a clinic menu as if the policy were a final monograph.

State licensure does not disappear in the meantime. The covered compounders are still a state-licensed pharmacy, a federal facility, or a licensed physician, and insanitary conditions are still prohibited [1][2]. A federal enforcement statement does not erase a state board's rules. If a board's rule is stricter, the stricter rule is the one the pharmacy has to be able to explain. This page is not legal advice to that pharmacy.

Sommar Club does not prescribe or sell these six. Nothing here is a suggestion to start them before a clinician has a reason.

FAQ

Is the policy permanent until the final rule? It is written to last until a final rule addresses each peptide, and HHS may revisit it sooner if safety or quality problems appear [1][2].

Can a patient sue to keep the policy in place? The notice says it does not establish any rights for any person [1].

Sources

1. HHS notice, FR Doc. 2026-22192, filed Oct 28, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf

2. HHS policy, interim status and condition 10. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Education only. Not medical or legal advice. As of Oct 29, 2026.